179 related articles for article (PubMed ID: 37909969)
1. Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N; Kita Y; Ito K; Kato M; Hatakeyama S; Matsushita Y; Naito S; Miyake M; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Nishiyama H; Kobayashi T; Kitamura H;
Anticancer Res; 2023 Nov; 43(11):5041-5050. PubMed ID: 37909969
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
Esagian SM; Khaki AR; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Msaouel P; Koshkin VS; Grivas P
BJU Int; 2021 Aug; 128(2):196-205. PubMed ID: 33556233
[TBL] [Abstract][Full Text] [Related]
3. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
5. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.
Winters BR; De Sarkar N; Arora S; Bolouri H; Jana S; Vakar-Lopez F; Cheng HH; Schweizer MT; Yu EY; Grivas P; Lee JK; Kollath L; Holt SK; McFerrin L; Ha G; Nelson PS; Montgomery RB; Wright JL; Lam HM; Hsieh AC
JCI Insight; 2019 May; 5(13):. PubMed ID: 31145100
[TBL] [Abstract][Full Text] [Related]
6. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.
Nishiyama N; Kobayashi T; Narita S; Hidaka Y; Ito K; Maruyama S; Mukai S; Tsutsumi M; Miki J; Okuno T; Yoshio Y; Matsumoto H; Shimazui T; Segawa T; Karashima T; Masui K; Fukuta F; Tashiro K; Imai K; Suekane S; Nagasawa S; Higashi S; Fukui T; Kojima T; Morita S; Ogawa O; Nishiyama H; Kitamura H;
J Geriatr Oncol; 2022 Jan; 13(1):88-93. PubMed ID: 34238726
[TBL] [Abstract][Full Text] [Related]
9. Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma - Subgroup Analysis of an Observational Study.
Heers H; DE Geeter P; Goebell PJ; Matz U; DE Schultz W; Edlich B; Retz M; Hegele A
Anticancer Res; 2017 Nov; 37(11):6437-6442. PubMed ID: 29061830
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
Zhai H; Wang Y; Chen Z; Wang Z; Xing J; Zhu X; Hao G
Int Urol Nephrol; 2024 Mar; 56(3):941-955. PubMed ID: 37847324
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma.
Khriguian J; Patrocinio H; Andonian S; Aprikian A; Kassouf W; Tanguay S; Cury FL
Pract Radiat Oncol; 2022; 12(1):e34-e39. PubMed ID: 34530170
[TBL] [Abstract][Full Text] [Related]
12. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
[TBL] [Abstract][Full Text] [Related]
13. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients.
Grasso M; Fishman AI; Cohen J; Alexander B
BJU Int; 2012 Dec; 110(11):1618-26. PubMed ID: 22458598
[TBL] [Abstract][Full Text] [Related]
14. Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?
Krabbe LM; Bagrodia A; Westerman ME; Gayed BA; Haddad AQ; Sagalowsky AI; Shariat SF; Kapur P; Lotan Y; Margulis V
World J Urol; 2016 Jan; 34(1):105-12. PubMed ID: 25991599
[TBL] [Abstract][Full Text] [Related]
15. Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma.
Silberstein JL; Power NE; Savage C; Tarin TV; Favaretto RL; Su D; Kaag MG; Herr HW; Dalbagni G
J Urol; 2012 Feb; 187(2):429-34. PubMed ID: 22177163
[TBL] [Abstract][Full Text] [Related]
16. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Eur Urol Focus; 2018 Dec; 4(6):946-953. PubMed ID: 28753881
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic management of upper tract urothelial cancer in a highly endemic area: A Taiwan nationwide collaborative study.
Chen YT; Yeh HC; Lee HY; Hsieh PF; Chou EC; Tsai YC; Hong JH; Huang CY; Jiang YH; Lee YK; Tseng JS; Yu CC; Chiang BJ; Hsueh TY; Wu CC; Tsai CY
Asian J Surg; 2023 Aug; 46(8):3058-3065. PubMed ID: 37525448
[TBL] [Abstract][Full Text] [Related]
18. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.
Yates DR; Catto JW
World J Urol; 2013 Feb; 31(1):21-9. PubMed ID: 22986906
[TBL] [Abstract][Full Text] [Related]
19. Histological variants and lymphovascular invasion in upper tract urothelial carcinoma can stratify prognosis after radical nephroureterectomy.
Takemoto K; Hayashi T; Hsi RS; Kobatake K; Sekino Y; Kitano H; Ikeda K; Goto K; Hieda K; Sentani K; Kajiwara M; Nishizaka T; Teishima J; Oue N; Hinata N
Urol Oncol; 2022 Dec; 40(12):539.e9-539.e16. PubMed ID: 36244916
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.
Simon CT; Skala SL; Weizer AZ; Ambani SN; Chinnaiyan AM; Palapattu G; Hafez K; Magers MJ; Kaffenberger SD; Spratt DE; Montgomery JS; Morgan TM; Udager AM; Lew M; Mehra R
Hum Pathol; 2019 Apr; 86():76-84. PubMed ID: 30537495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
